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Abstract 
Background: Extended-Spectrum β-Lactamase (ESBL) producing Enterobacteriaceae have become widespread in hospitals and 
are increasing in community settings where they cause a variety of infections. In addition to hydrolyzing most beta-lactam agents, 
bacteria harboring these enzymes display resistance to other unrelated antimicrobial agents and thus often pose a therapeutic 
dilemma. Though these resistance patterns have been studied elsewhere within Africa, such data from hospitals in Kenya are 
scanty. We therefore undertook to determine these patterns at the Aga Khan University hospital by studying multidrug resistant 
Escherichia coli and Klebsiella pneumoniae isolates from patients’ samples.
Findings: A total of 159 isolates (109 E. coli and 50 K. pneumoniae) were confirmed as ESBL producers and tested against 
eighteen antimicrobials. The proportion of resistant isolates was high (>80%) for the antimicrobials tested with the exception of 
the carbapenems (<1%), nitrofurantoin (23%) and gentamicin (63%). Klebsiella pneumoniae had a higher proportion of isolates 
resistant to ceftazidime, gentamicin and nitrofurantoin (P < 0.05) than E. coli which had a higher proportion of isolates resistant to 
ciprofloxacin, levofloxacin and tetracycline (P < 0.05). 
Conclusions: In our study, antimicrobial coresistance is common in ESBL producers; however resistance to carbapenems is low 
and these drugs would be the appropriate empiric therapy for serious or life threatening systemic infections. Nitrofurantoin retains 
good activity among the multidrug resistant isolates and can be the drug of choice for non-complicated urinary tract infections 
due to ESBL producing E. coli. 
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Background
The precise definition of the term Extended-Spectrum 
β-Lactamase (ESBL) remains unclear but is generally used 
to refer to any β-lactamase, ‘generally acquired rather than 
inherent to a species, that is either able to confer resistance 
to oxyimino-cephalosporins (but not carbapenems), or that 
has an increased ability to do so, as compared with classic 
members of its genetic family’ [1].
ESBL producing strains of Enterobacteriaceae have emerged 
as a major problem in hospitalized as well as community based 
patients [2]. These organisms are responsible for a variety of 
infections like urinary tract infection (UTI), septicemia, hospital 
acquired pneumonia, intra-abdominal abscess, brain abscess 
and device related infections.
Organisms producing ESBLs are clinically relevant and remain 
an important cause of failure of therapy with cephalosporins 
[3]. ESBLs are primarily produced by the Enterobacteriaceae 
family, in particular Klebsiella pneumoniae and Escherichia coli [4].
 Bacteria harboring ESBLs may also acquire and most often 
exhibit additional resistances to other antimicrobial classes such 
as the quinolones, tetracyclines, cotrimoxazole, trimethoprim, 
and aminoglycosides, which further limits therapeutic options 
and thus pose a therapeutic dilemma [5-8]. 
The Aga Khan University hospital (AKUH) is a private tertiary 
institution located in Nairobi, Kenya, with twenty satellite clinics 
spread across the country that send specimens for culture to 
the main laboratory. Among the Enterobacteriaceae, E. coli 
and K. pneumoniae are the two most isolated organisms from 
patients’ samples in the hospital’s microbiology section and 
ESBL producing isolates account for approximately 8% of the 
two species. Cephalosporins are among the most prescribed 
antibiotics in the hospital. In the year 2009 about 250,000 doses 
of ceftriaxone were consumed in the outpatient department 
alone. The antibiotic susceptibility profiles of these ESBL 
producing isolates have not been previously described in this 
hospital and are the focus of this study.
Methods
Three hundred thirty six multidrug resistant isolates cultured 
from clinical specimens and which were reported as E. coli 
and K. pneumoniae by use of routine bench biochemical tests 
and stored at -800C in a broth medium with glycerol during 
the period 2007 to 2009 were included in the study. Only one 
isolate per patient was included. The isolates were revived on 
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MacConkey media plates. Confirmation of ESBL production 
was done using the combined disc method [ceftazidime 
(CAZ 30μg) and cefotaxime (CTX 30μg) in combination 
with clavulanate (CLA 10μg), Becton Dickinson, New Jersey, 
USA] as per the Clinical Laboratory Standards Institute (CLSI 
2009) guidelines on Mueller Hinton with 5% sheep blood 
agar plates, and antibiotic susceptibility performed using 
VITEK 2 (version 4.01, bioMerieux, Marcy-l’Etoile, France) and 
interpreted using the same CLSI 2009 guidelines. Klebsiella 
pneumoniae K6 ATCC 700603 (ESBL producer) and Escherichia 
coli ATCC 25922 (non-ESBL producer) served as the positive 
and negative controls respectively.
Eighteen antimicrobial agents were included; amoxicillin/
clavulanate, ampicillin, ceftazidime, cefuroxime, ciprofloxacin, 
Inpatient Outpatient
Specimen type E. coli K. pneumoniae E. coli K. pneumoniae Total
ABDOMINAL DRAIN 1 0 0 0 1
ASITIC FLUID 1 0 0 0 1
AXILLA SWAB 2 0 0 0 2
BRONCHIAL LAVAGE 
FLUID
0 1 0 0 1
BLOOD 1 1 0 0 2
CATHETER TIP 0 1 0 0 1
CSF 1 0 0 0 1
ENDOCERVICAL SWAB 0 0 1 0 1
GROIN SWAB 1 0 0 0 1
JOINT ASPIRATE 0 1 0 0 1
NASAL SWAB 0 1 0 0 1
PUS SWAB 5 8 6 2 21
SPUTUM 2 3 0 1 6
TRACHEAL ASPIRATE 1 3 0 0 4
URINE 23 15 64 13 115
Total 38 34 71 16 159
Table1. Distribution of clinical specimens and isolates cultured.
Antibiotic Resistant Sensitive
No (%) No (%)
Amoxicillin/Clavulanate 159 (100%) 0
Ampicillin 159 (100%) 0
Ceftazidime 144 (90.6%) 15 (9.4%)
Cefuroxime 158 (99.4%) 1(0.6%)
Ciprofloxacin 132 (83%) 27 (17%)
Cefpodoxime 158 (99.4) 1 (0.6%)
Cefotaxime 158 (99.4%) 1 (0.6%)
Gentamicin 101 (63.6%) 58 (36.4%)
Imipenem 1 (0.6%) 158 (99.4%)
Levofloxacin 128 (80.5%) 31 (19.5%)
Meropenem 1 (0.6%) 158 (99.4%)
Nitrofurantoin 37 (23.3%) 122 (76.7%)
Piperacillin 159 (100%) 0
Roxithromycin 159 (100%) 0
Sulfamethoxazole/Trimethoprime 144 (90.6%) 15 (9.4%)
Teteracycline 131 (82.4%) 28 (17.6%)
Tobramycin 131 (82.4%) 28 (17.6%)
Tazobactam/Piperacillin 154 (96.9%) 5 (3.1%)
Table2. Antibiotic susceptibilities of the isolates n=159.
cefpodoxime, cefotaxime, gentamicin, imipenem, levofloxacin, 
meropenem, nitrofurantoin, piperacillin, roxithromycin, 
sulfamethoxazole/trimethoprime, teteracycline, tobramycin, 
and tazobactam/piperacillin. 
Data were analyzed using the statistical package for social 
sciences (SPSS 15.0, IBM SPSS, New York, USA).
Contingency table analysis was done by a chi-square test 
or two-tailed Fisher’s exact test where applicable. A p-value 
of less than 0.05 was considered as statistically significant. 
Ethical approval was granted by the Aga Khan University 
Hospital Nairobi Ethics Committee.
Findings
Isolate characteristics
Out of the 336 isolates initially included, 177 isolates could not 
either be revived, did not have patient details, were neither E. 
coli nor K. pneumoniae on retesting with VITEK 2, or were not 
ESBL producers and therefore excluded leaving 159 isolates.
A hundred and nine of the isolates (68.6%) were E. coli and 
50 (31.4%) were K. pneumoniae. Outpatient specimens were 87 
(45.3%) and inpatient 72 (45.3%). Escherichia coli were isolated 
more frequently in outpatients than K. pneumoniae (p < 0.05).
Urine was the most common specimen processed with 115 
(72%) of the samples. More than half of the urine samples 
were from outpatients. Other specimens were fewer and 
mostly from in-patients (Table 1). The ages of patients from 
whom the specimens were recovered ranged from 2 days to 
90 years with a median of 42 years.
Antibiotic susceptibility patterns 
A large proportion of the isolates (> 80%) were resistant to all 
classes of antibiotics tested apart from the carbapenems to 
which resistance was found in a single isolate. The proportion 
of isolates resistant to nitrofurantoin was substantially lower 
at 23% and 63% for gentamicin (Table 2).
There were significant species specific differences in the 
resistance patterns to some antibiotics. Klebsiella pneumoniae 
had a higher proportion of isolates resistant to ceftazidime, 
gentamicin and nitrofurantoin than E. coli isolates. In turn E. coli 
had a higher proportion of isolates resistant to ciprofloxacin, 
levofloxacin and tetracycline (Table 3).
Discussion
Our study analyzed 159 isolates from in-patients and out-
patients, thus encompassing both hospital and community 
acquired infections due to ESBL producing E. coli and K. 
pneumoniae.
The two bacteria species studied had high proportions 
of resistant isolates to most antimicrobial agents with the 
exception of carbapenems and nitrofurantoin.
Similar findings have been reported in other studies in Iran 
and Tanzania [9,10]. In these two studies imipenem was shown 
to be the most active antibiotic against the ESBL producing 
isolates and nitrofurantoin showed moderate activity.




The finding that nitrofurantoin remains active in the majority 
of isolates is clinically important to the outpatient setting, 
where most of the isolates from urine tended to be E. coli or 
K. pneumoniae.
Nitrofurantoin can therefore be used effectively for most 
non-life threatening urinary tract infections with little regard 
to the antibiotic resistance mechanisms at play among ESBL 
producing isolates. From our experience many clinicians 
prefer to prescribe other drugs yet nitrofurantoin remains 
effective in most cases where there are multiple resistances 
as is also evident in other studies [11,12].
Given the popularity of fluoroquinolones in treating a 
variety of infections including respiratory, gastrointestinal and 
urinary tract infections, the two drugs tested (ciprofloxacin 
and levofloxacin) fared poorly with >80% of the isolates 
showing resistance to both. This is not surprising among 
ESBL producers and this phenomenon is well described in 
the literature. The CTX-M genotype is the one that has most 
been associated with this resistance [6,13].
The CTX-M genotype has been documented locally. A 
previous study done in this University hospital using part 
of the 159 isolates found the CTX-M genotype the most 
predominant being present in 46 (88.5%) of the 52 ESBL 
isolates tested [14]. It has also been suggested that the use 
of fluoroquinolones selects for and results in the spread of 
this genotype [15].
The resistance to carbapenems was low in our study and 
the single isolate that displayed resistance to the two drugs 
in this class needs further investigation to determine the 
probable additional mechanism of resistance. While this class 
of drugs remains useful for treating serious infections due to 
multidrug resistant enteric bacteria in our set up, the single 
isolate resistant to carbapenems is clinically relevant and 
suggests that this pattern of resistance should be monitored 
closely by microbiology laboratories.
The clinical utility of cephalosporins even with the evidence 
of in vitro activity in isolates that are ESBL producers remain 
controversial. The CLSI guidelines state they should be reported 
as resistant, a position that is held by some researchers while 
others suggest that there may be a limited clinical role for 
Antibiotic             Sensitivity E. coli (n=109) K. pneumoniae (n=50) P-value 
Ceftazidime                     R 95 49
0.038
       S 14 1
Ciprofloxacin        R 101 31
<0.001
       S 8 19
Levofloxacin        R 99 29
<0.001
       S 10 21
Nitrofurantoin        R 12 25
<0.001
       S 97 25
Tetracycline        R 96 35
0.005
       S 13 15
Table3. Significant species specific differences in antimicrobial 
resistance.
R=resistant, S=sensitive
cephalosporins with activity against ESBL producers [16]. Our 
data suggests that cephalosporins would be of limited use in 
the treatment of ESBL related infections in our institution as the 
proportion of resistant isolates was high. These observations 
also apply to the β-lactam/β-lactam inhibitor combinations 
for which we observed a high proportion of isolates with 
MICs in the resistant range. A possible explanation for the 
latter observation is the presence of additional resistance 
mechanisms which as noted above may be acquired together 
with ESBLs. However, these additional mechanisms were not 
specifically looked for in this study.
The screening for ESBL production is not routinely done 
in many clinical laboratories in this country and the impact 
of treatment failure associated with these infections when 
treated with cephalosporins is not well documented. 
Conclusions 
ESBL producing E. coli and K. pneumoniae display multiple 
resistances to various classes of antimicrobials and are 
therefore important to identify and treat accordingly. In 
our study the carbapenems and nitrofurantoin retain good 
activity and would thus be the drugs of choice for empiric 
therapy in life threatening infections and non-complicated 
urinary tract infections respectively. There is need to carry 
out more studies to determine the epidemiology of ESBL 
related infections and the associated clinical burden locally.
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